Arcturus Therapeutics Holdings Inc (ARCT), a global messenger RNA medicine company which made significant strides in advancing its pipeline in 2023, expects to launch its first product in Japan this year.
Kostaive, a self-amplifying mRNA COVID-19 vaccine for primary vaccination and booster for adults 18 years and older, developed by Arcturus in partnership with CSL, is expected to be launched in Japan this year. The vaccine was approved by Japan's Ministry of Health, Labor and Welfare last November.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com